ANALYST RECOMMENDATIONS : Accenture, Biogen, Fedex, Netflix, Philip Morris...

Every day, find a selection of analysts' recommendations covering North America and the UK. The list only includes companies that have been the subject of a change of opinion or price target, or of a new coverage. It may be updated during the session. This information is used to shed light on the movements of certain stocks or the market sentiment on a company.

 

• Accenture: Wedbush adjusts price target to $300 from $350; outperform rating kept.
• AGCO: Baird initiated coverage with a recommendation of outperform. PT rises 65% to $156.
• Biogen: BMO Capital Markets upgrades to outperform from market perform. PT jumps 82% to $360.
• CVS Group: Jefferies remains Buy with a price target reduced from 2110 to 1970 GBp.
• Dechra Pharmaceuticals: Jefferies maintains a Hold rating with a price target reduced from 3,630 to 2,880 GBp.
• Endava: Wedbush adjusts price target to $90 from $120, outperform rating kept.
• Fedex: Bernstein lowers price target to $212 from $316, maintains outperform rating.
• Games Workshop: Jefferies remains Buy with a price target reduced from 9700 to 8700 GBp.
• Lennar: Goldman Sachs raises price target to $90 from $89, maintains buy rating.
• Micron Technology: Bernstein lowers price target to $90 from $94, maintains outperform rating.
• Netflix: Atlantic Equities raised its recommendation to overweight from neutral. PT gains 26% to $283.
• Philip Morris: Credit Suisse reinstated coverage with a recommendation of neutral. PT jumps 23% to $107.
• SouthState Corp: Piper Sandler upgrades to overweight from neutral. PT up 24% to $96.
• Treatt: HSBC starts tracking at hold, targeting GBp 600.
• Truist Financial: Piper Sandler upgraded to overweight from neutral. PT up 28% to $55.